Berberine behind the thriller of marked symptomatic bradycardia

Margherita Cannillo1, Simone Frea, Cristina Fornengo

  • 1Margherita Cannillo, Simone Frea, Cristina Fornengo, Elisabetta Toso, Fiorenzo Gaita, Division of Cardiology, Cardiovascular Department, AOU S. Giovanni Battista di Torino and University of Torino, 10100 Torino, Italy.

Insights

Berberine, a traditional Chinese medicine, can cause serious heart rhythm issues like bradycardia and arrhythmias in hypervagotonic individuals. Careful consideration of berberine use is advised for these patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Traditional Chinese Medicine

Background:

  • Berberine is a compound used in Traditional Chinese Medicine for various conditions, including cardiovascular diseases.
  • It is generally considered to have a good safety profile.
  • Hypervagotonia, a state of increased parasympathetic nervous system activity, can predispose individuals to certain cardiovascular events.

Purpose of the Study:

  • To report a case of adverse cardiovascular effects associated with berberine use.
  • To investigate the potential proarrhythmic effects of berberine in individuals with a hypervagotonic state.
  • To highlight the importance of considering patient-specific factors when prescribing berberine.

Main Methods:

  • A case report of a 53-year-old male experiencing fatigue and dyspnea after initiating berberine for hypercholesterolemia.
  • Electrocardiogram (ECG) and ergometric stress testing were performed.
  • A 10-day berberine washout period was implemented, followed by repeat testing and Holter monitoring.

Main Results:

  • Initial ECG revealed sinus bradycardia, atrioventricular block, and junctional rhythm.
  • Stress testing showed reduced chronotropic competence and arrhythmias.
  • After berberine cessation, symptoms resolved, stress test normalized, and Holter monitoring indicated a latent hypervagotonic state.

Conclusions:

  • This case suggests berberine can induce bradycardic and antiarrhythmic effects that may become proarrhythmic in hypervagotonic individuals.
  • The drug's use warrants caution in patients with a hypervagotonic state, even without conditions promoting drug accumulation.
  • This highlights the need for personalized risk assessment when using berberine.

Related Concept Videos

Decreased pulse rate01:14

Decreased pulse rate

Bradycardia is a medical condition in which the heart rate is slower than normal. It occurs when the heart's natural pacemaker, the sinus node, generates slower electrical impulses than the standard rhythm. In adults, bradycardia is diagnosed when the pulse rate falls below 60 beats per minute, indicating a deviation from the normal heart rate range.
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with bradycardia...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...